Techpool Bio-Pharma Co., Ltd.   Report issue

For profit Phase 4
Founded: Guangzhou China (1993)
Status: No NME R&D (1993)

Organization Overview

First Clinical Trial
2010
NCT01132521
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2016

Timeline

NOW
  • Now

Active Ingredients

Drugs in Phase 4 Trials (2)

kallikrein (1 trial)

ulinastatin (4 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Acute Lung Injury (Phase 2)

Cerebral Infarction (Phase 4)

Heart Defects, Congenital (Phase 4)

Heart Diseases (Phase 4)

Infarction (Phase 4)

Pancreatitis (Phase 4)

Respiratory Distress Syndrome (Phase 2)

Respiratory Distress Syndrome, Newborn (Phase 2)

Sepsis (Phase 4)

Shock (Phase 4)

Shock, Septic (Phase 4)

Syndrome (Phase 2)

Toxemia (Phase 4)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 5
  • # of Trial APIs: 2